The elderly account for the majority of medical spending in many countries, raising concerns about potentially unnecessary spending, especially during the final months of life. Using a well-defined ...

Key points A 56-year-old woman presented to the emergency department with a 2-day history of central chest pain and dyspnea. Her medical history included having had a myocardial infarction (MI) with n ...

While there are therapies to aid in overall heart health, there are very few preventative therapies for heart failure after a significant heart attack, a serious condition that has a very significant ...

The comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) ...

THE recent availability of pure L-nor-epinephrine (arterenol, nor-adrenaline) has permitted evaluation of its clinical usefulness as a pressor agent. Preliminary reports 1–7 have suggested beneficial ...

DelveInsight’s, “Myocardial Infarction Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 40+ pipeline drugs in Myocardial Infarction pipeline landscape. It covers ...

Early substrate-based radiofrequency catheter ablation (RFCA) was associated with reduced risk of implantable cardioverter defibrillator (ICD) therapies, but with no meaningful difference ...

In the absence of contraindications, aspirin should be administered to all patients presenting with acute coronary syndromes.14 Data from the second International Study of Infarct Survival (ISIS-2), ...

The world's first clinical trial to test glenzocimab as a potential new drug to improve the long-term outcomes for heart attack patients will take place in the UK. Glenzocimab is a humanised ...